CBD /

 

Loading...
Country's Decision or any other Communication (DEC)
  |  
BCH-DEC-BR-294442-1   |   PDF   |   Print   |  
| 
|  Close
last updated: 29 Apr 2026
Amendment
No
General Information
Brazil
Commercial Release of the Biotech Vac COX vaccine, derived from Genetically Modified Microorganism (MGM) - Technical Opinion No. 8962/2024.
EN
07 Mar 2024
No
Subject of the decision, notification, communication or declaration
  • Decision on LMOs for intentional introduction into the environment (according to Article 10 or domestic regulatory framework)
  • Decision on LMOs for direct use as food or feed, or for processing (Article 11, LMOs-FFP)
LMOs for intentional introduction into the environment
No
Yes
Yes
Yes
Yes
LMOs for direct use as food or feed, or for processing (LMOs-FFP)
  • LMOs for processing
No
Result of the decision
Approval of the import and/or use of the LMO(s) without conditions
Information sharing with other databases
Yes
No
No
LMO identification & risk assessment
  • BCH-LMO-SCBD-300065-1 Living Modified Organism Biotech Vac COX
    Vetanco do Brasil Importação e Exportação Ltda(Vetanco) | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
  • BCH-RA-BR-294441-1 Risk Assessment generated by a regulatory process Risk assessment of the Biotech Vac COX vaccine, derived from Genetically Modified Microorganism (MGM) - Technical Opinion No. 8962/2024.
    Biotech Vac COX vaccine | Production of medical or pharmaceutical compounds (human or animal)
Document on the decision, communication, notification or declaration

Quick links

About the BCH About the Cartagena Protocol Supplementary Protocol

Sign in Search records Submit records
Registries: LMO-Organism-Gene Country Profiles
National Report Analyzer

Forums BCH Announcements

Need help?

Knowledge Base FAQs UNEP eLearning Training Site

Contact us at: bch@cbd.int
BCH Biosafety Clearing-House
Subscribe to e-mail notifications
Subscribe to our newsletter